查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1856929

感染疾病控制市場預測至2032年：按產品、類型、最終用戶和地區分類的全球分析

Infectious Disease Management Market Forecasts to 2032 - Global Analysis By Product (Diagnostics, Therapeutics, Vaccines), Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計 2025 年全球感染疾病控制市場規模將達到 233 億美元，到 2032 年將達到 389 億美元，預測期內複合年成長率為 7.6%。

感染疾病防治是指對由細菌、病毒、真菌和寄生蟲等病原體引起的疾病進行預防、診斷、治療和管理的綜合方法。它包括監測、利用診斷工具進行早期檢測、及時醫療干預以及限制傳播的公共衛生策略。疫苗接種計劃、抗菌治療和隔離措施是重要的組成部分。有效的防治還包括教育、衛生管理以及為因應疫情爆發和疫情而進行的全球合作。生物技術和數據分析的進步使感染疾病防治更加積極主動，使醫療衛生系統能夠快速回應並減少疫情對人群的影響。

全球感染風險日益增加

全球感染疾病的日益增加是推動市場發展的主要因素。新冠病毒、流感以及新興病原體等病毒的頻繁爆發提高了全球的防控意識，並提升了對健全的疾病防治體系的需求。各國政府和醫療機構正在增加對監測、診斷和治療基礎設施的投入，以降低風險。這種對感染疾病防治日益成長的迫切性正在刺激市場創新和擴張，使感染疾病防治成為各地區的首要任務。

先進診斷工具高成本

先進診斷工具的高昂成本是限制市場成長的主要因素。分子檢測、基因定序和快速診斷等技術需要對設備、培訓和維護進行大量投資。這些成本對於中低收入國家的醫療衛生系統而言可能難以承受，從而限制了及時、準確疾病檢測的普及。因此，醫療基礎設施的差異和經濟負擔阻礙了有效感染疾病控制方案的廣泛應用，減緩了市場滲透率。

診斷技術的進步

診斷技術的進步為市場帶來了廣泛的機會。即時檢測、人工智慧主導的分析以及攜帶式診斷設備等創新技術能夠快速且準確地檢測病原體。這些工具透過促進早期療育和減少感染，改善了患者的治療效果。隨著醫療系統擁抱數位轉型和個人化醫療，對尖端診斷技術的需求持續成長。預計這一趨勢將推動市場顯著成長，並重塑感染疾病管理格局。

監管障礙

監管障礙對市場構成顯著威脅。新診斷試劑、治療藥物和疫苗的嚴格核准流程可能會延遲產品上市，並在疫情爆發期間限制其使用。遵守各項國際標準也為製造商和醫療服務提供者帶來了複雜性。這些挑戰會減緩創新步伐，並阻礙對新出現的健康威脅做出及時反應。透過簡化政策和加強全球合作來解決監管瓶頸，對於快速部署有效的疾病控制方案至關重要。

新冠疫情的影響：

新冠疫情對感染疾病防治市場產生了重大影響，加速了對診斷、疫苗和治療方案的需求。疫情暴露了全球醫療基礎設施的不足，凸顯了快速反應系統的必要性。各國政府和組織在研究、檢測和公共衛生領域投入巨資，推動了創新與合作。疫情也促進了數位醫療技術和遠端醫療的應用。儘管疫情擾亂了供應鏈並加劇了資源緊張，但最終也透過持續的改進重塑了市場格局。

預計疫苗板塊在預測期內將成為最大的板塊。

預計在預測期內，疫苗領域將佔據最大的市場佔有率，因為疫苗在預防感染疾病傳播和減輕醫療負擔方面發揮關鍵作用。新冠肺炎疫苗宣傳活動的成功凸顯了疫苗的重要性，促使相關領域的投資和研發不斷增加。 mRNA技術的進步、全球疫苗接種計劃以及公眾意識的提高都推動了該領域的成長。隨著新病原體的出現，疫苗仍然是主動疾病控制和公共衛生策略的基石。

預計真菌感染疾病細分市場在預測期內將實現最高的複合年成長率。

由於真菌疾病病例不斷增加，尤其是在免疫力人群中，對專業診斷和治療的需求日益成長，預計真菌感染疾病市場在預測期內將呈現最高的成長率。氣候變遷、抗生素抗藥性和住院率上升是導致真菌感染疾病盛行率上升的原因。抗真菌療法的創新和檢測方法的改進正在改善患者的治療效果。隨著人們對真菌感染疾病的認知不斷提高以及相關研究的深入，真菌感染疾病管理市場預計將快速成長，超過其他細分市場。

比最大的地區

預計亞太地區將在預測期內佔據最大的市場佔有率。該地區人口密度高、疫情頻繁爆發以及不斷完善的醫療基礎設施，推動了對有效疾病控制解決方案的需求。中國、印度和日本等國家正在加大對診斷、疫苗接種計畫和公共衛生措施的投入。政府支持、公眾意識的提高以及技術的應用，進一步推動了市場成長。亞太地區對感染疾病控制的策略重視，使其在全球市場中佔據了有利地位。

複合年成長率最高的地區：

預計北美地區在預測期內將實現最高的複合年成長率，這得益於該地區強大的醫療基礎設施、先進的研究能力和積極的公共衛生政策，這些都為快速的技術創新提供了支持。對個人化醫療、數位診斷和疫苗研發的強勁需求將推動市場成長。對生物技術的投資以及政府與私營部門之間的合作正在促進市場擴張。北美在技術進步和疾病監測方面持續保持領先地位，從而推動了感染疾病控制市場的蓬勃發展。

免費客製化服務：

訂閱本報告的用戶可享有以下免費客製化服務之一：

  • 公司簡介
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行市場估算、預測和複合年成長率分析（註：基於可行性檢查）
  • 競爭基準化分析
    • 基於產品系列、地域覆蓋和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 原始研究資料
    • 次級研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球感染疾病控制市場（依產品分類）

  • 診斷
    • PCR和分子診斷
    • 免疫檢測
    • 快速檢測套組
  • 治療藥物
    • 抗生素
    • 抗病毒藥物
    • 抗真菌藥物
    • 抗寄生蟲藥物
  • 疫苗
    • 病毒疫苗
    • 細菌疫苗

6. 全球感染疾病控制市場（按類型分類）

  • 細菌感染疾病
    • 結核
    • 肺炎
  • 病毒感染
    • 愛滋病毒/愛滋病
    • 流感
    • 肝炎
    • COVID-19
  • 黴菌感染疾病
  • 寄生蟲感染疾病

7. 全球感染疾病控制市場（依最終用戶分類）

  • 醫院
  • 診斷實驗室
  • 門診治療中心
  • 研究和學術機構
  • 家庭醫療保健
  • 數位健康解決方案
  • 其他最終用戶

8. 全球感染疾病控制市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第9章：重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與併購
  • 新產品上市
  • 業務拓展
  • 其他關鍵策略

第10章：企業概況

  • Pfizer
  • Gilead Sciences
  • Johnson & Johnson
  • Merck & Co.
  • GlaxoSmithKline（GSK）
  • Roche
  • Sanofi
  • Novartis
  • AstraZeneca
  • AbbVie
  • Takeda Pharmaceutical
  • BioNTech
  • Moderna
  • Eli Lilly and Company
  • Bayer AG
Product Code: SMRC31793

According to Stratistics MRC, the Global Infectious Disease Management Market is accounted for $23.3 billion in 2025 and is expected to reach $38.9 billion by 2032 growing at a CAGR of 7.6% during the forecast period. Infectious disease management refers to the comprehensive approach used to prevent, diagnose, treat, and control diseases caused by pathogens such as bacteria, viruses, fungi, and parasites. It involves surveillance, early detection through diagnostic tools, timely medical intervention, and public health strategies to limit transmission. Vaccination programs, antimicrobial therapies, and quarantine measures are key components. Effective management also includes education, sanitation, and global collaboration to address outbreaks and pandemics. With advancements in biotechnology and data analytics, infectious disease management has become more proactive, enabling healthcare systems to respond swiftly and reduce the impact of contagious illnesses on populations.

Market Dynamics:

Driver:

Rising global infectious risks

The increasing prevalence of infectious diseases worldwide is a major driver of the market. Frequent outbreaks of viruses like COVID-19, influenza, and emerging pathogens have heightened global awareness and demand for robust disease control systems. Governments and healthcare providers are investing in surveillance, diagnostics, and treatment infrastructure to mitigate risks. This growing urgency to contain and prevent infections is fueling innovation and expansion in the market, making infectious disease management a top priority across regions.

Restraint:

High cost of advanced diagnostics

The high cost of advanced diagnostic tools poses a significant restraint to market growth. Technologies such as molecular testing, genomic sequencing, and rapid diagnostics require substantial investment in equipment, training, and maintenance. These expenses can be prohibitive for healthcare systems in low- and middle-income countries, limiting access to timely and accurate disease detection. As a result, disparities in healthcare infrastructure and affordability hinder the widespread adoption of effective infectious disease management solutions, slowing market penetration.

Opportunity:

Advancements in diagnostics

Technological advancements in diagnostics offer a promising opportunity for the market. Innovations like point-of-care testing, AI-driven analysis and portable diagnostic devices enable faster, more accurate detection of pathogens. These tools improve patient outcomes by facilitating early intervention and reducing transmission. As healthcare systems embrace digital transformation and personalized medicine, the demand for cutting-edge diagnostics continues to rise. This trend is expected to drive significant growth and reshape the landscape of infectious disease management.

Threat:

Regulatory hurdles

Regulatory hurdles present a notable threat to the market. Stringent approval processes for new diagnostics, treatments, and vaccines can delay product launches and limit access during critical outbreaks. Compliance with varying international standards adds complexity for manufacturers and healthcare providers. These challenges may slow innovation and hinder timely responses to emerging health threats. Addressing regulatory bottlenecks through streamlined policies and global collaboration is essential to ensure rapid deployment of effective disease management solutions.

Covid-19 Impact:

The Covid-19 pandemic had a profound impact on the infectious disease management market, accelerating demand for diagnostics, vaccines, and treatment solutions. It exposed gaps in global healthcare infrastructure and emphasized the need for rapid response systems. Governments and organizations invested heavily in research, testing, and public health initiatives, driving innovation and collaboration. The pandemic also spurred adoption of digital health technologies and telemedicine. While it disrupted supply chains and strained resources, Covid-19 ultimately reshaped the market with lasting improvements.

The vaccines segment is expected to be the largest during the forecast period

The vaccines segment is expected to account for the largest market share during the forecast period because Vaccines play a crucial role in preventing the spread of infectious diseases and reducing healthcare burdens. The success of COVID-19 vaccination campaigns has reinforced their importance, prompting increased investment and development. Advances in mRNA technology, global immunization programs, and rising public awareness contribute to the segment's growth. As new pathogens emerge, vaccines remain a cornerstone of proactive disease management and public health strategy.

The fungal infections segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the fungal infections segment is predicted to witness the highest growth rate, due to rising cases of fungal diseases, particularly among immune compromised individuals, are driving demand for specialized diagnostics and treatments. Climate change, antibiotic resistance, and increased hospitalizations contribute to the growing prevalence of fungal infections. Innovations in antifungal therapies and improved detection methods are enhancing patient care. As awareness and research expand, the market for managing fungal infections is expected to grow rapidly, outpacing other segments.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to region's dense population, frequent outbreaks, and expanding healthcare infrastructure drive demand for effective disease control solutions. Countries like China, India, and Japan are investing in diagnostics, vaccination programs, and public health initiatives. Government support, rising awareness, and technological adoption further boost market growth. Asia Pacific's strategic focus on infectious disease preparedness positions it as a dominant force in the global market.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to region's strong healthcare infrastructure, advanced research capabilities, and proactive public health policies support rapid innovation. High demand for personalized medicine, digital diagnostics, and vaccine development fuels growth. Investments in biotechnology and collaborations between government and private sectors enhance market expansion. As North America continues to lead in technological advancements and disease surveillance, its infectious disease management market is set to surge.

Key players in the market

Some of the key players in Infectious Disease Management Market include Pfizer, Gilead Sciences, Johnson & Johnson, Merck & Co., GlaxoSmithKline (GSK), Roche, Sanofi, Novartis, AstraZeneca, AbbVie, Takeda Pharmaceutical, BioNTech, Moderna, Eli Lilly and Company and Bayer AG.

Key Developments:

In March 2025, Harbour BioMed and AstraZeneca have embarked on a global collaboration to discover and develop next-generation multi-specific antibodies targeting immunology, oncology, and other therapeutic areas.

In March 2025, Bayer and Neste entered a strategic partnership to develop winter canola as a sustainable feedstock for renewable fuels. This collaboration aims to establish a U.S.-based winter canola ecosystem, enhancing soil health and carbon sequestration.

Products Covered:

  • Diagnostics
  • Therapeutics
  • Vaccines

Types Covered:

  • Bacterial Infections
  • Viral Infections
  • Fungal Infections
  • Parasitic Infections

End Users Covered:

  • Hospitals
  • Diagnostic Laboratories
  • Ambulatory Care Centers
  • Research & Academic Institutes
  • Home Healthcare
  • Digital Health Solutions
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Infectious Disease Management Market, By Product

  • 5.1 Introduction
  • 5.2 Diagnostics
    • 5.2.1 PCR & Molecular Diagnostics
    • 5.2.2 Immunoassays
    • 5.2.3 Rapid Test Kits
  • 5.3 Therapeutics
    • 5.3.1 Antibiotics
    • 5.3.2 Antivirals
    • 5.3.3 Antifungals
    • 5.3.4 Antiparasitic Drugs
  • 5.4 Vaccines
    • 5.4.1 Viral Vaccines
    • 5.4.2 Bacterial Vaccines

6 Global Infectious Disease Management Market, By Type

  • 6.1 Introduction
  • 6.2 Bacterial Infections
    • 5.2.1 Tuberculosis
    • 5.2.2 Pneumonia
  • 6.3 Viral Infections
    • 5.3.1 HIV/AIDS
    • 5.3.2 Influenza
    • 5.3.3 Hepatitis
    • 5.3.4 COVID-19
  • 6.4 Fungal Infections
  • 6.5 Parasitic Infections

7 Global Infectious Disease Management Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Diagnostic Laboratories
  • 7.4 Ambulatory Care Centers
  • 7.5 Research & Academic Institutes
  • 7.6 Home Healthcare
  • 7.7 Digital Health Solutions
  • 7.8 Other End Users

8 Global Infectious Disease Management Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Pfizer
  • 10.2 Gilead Sciences
  • 10.3 Johnson & Johnson
  • 10.4 Merck & Co.
  • 10.5 GlaxoSmithKline (GSK)
  • 10.6 Roche
  • 10.7 Sanofi
  • 10.8 Novartis
  • 10.9 AstraZeneca
  • 10.10 AbbVie
  • 10.11 Takeda Pharmaceutical
  • 10.12 BioNTech
  • 10.13 Moderna
  • 10.14 Eli Lilly and Company
  • 10.15 Bayer AG

List of Tables

  • Table 1 Global Infectious Disease Management Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Infectious Disease Management Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Infectious Disease Management Market Outlook, By Diagnostics (2024-2032) ($MN)
  • Table 4 Global Infectious Disease Management Market Outlook, By PCR & Molecular Diagnostics (2024-2032) ($MN)
  • Table 5 Global Infectious Disease Management Market Outlook, By Immunoassays (2024-2032) ($MN)
  • Table 6 Global Infectious Disease Management Market Outlook, By Rapid Test Kits (2024-2032) ($MN)
  • Table 7 Global Infectious Disease Management Market Outlook, By Therapeutics (2024-2032) ($MN)
  • Table 8 Global Infectious Disease Management Market Outlook, By Antibiotics (2024-2032) ($MN)
  • Table 9 Global Infectious Disease Management Market Outlook, By Antivirals (2024-2032) ($MN)
  • Table 10 Global Infectious Disease Management Market Outlook, By Antifungals (2024-2032) ($MN)
  • Table 11 Global Infectious Disease Management Market Outlook, By Antiparasitic Drugs (2024-2032) ($MN)
  • Table 12 Global Infectious Disease Management Market Outlook, By Vaccines (2024-2032) ($MN)
  • Table 13 Global Infectious Disease Management Market Outlook, By Viral Vaccines (2024-2032) ($MN)
  • Table 14 Global Infectious Disease Management Market Outlook, By Bacterial Vaccines (2024-2032) ($MN)
  • Table 15 Global Infectious Disease Management Market Outlook, By Type (2024-2032) ($MN)
  • Table 16 Global Infectious Disease Management Market Outlook, By Bacterial Infections (2024-2032) ($MN)
  • Table 17 Global Infectious Disease Management Market Outlook, By Tuberculosis (2024-2032) ($MN)
  • Table 18 Global Infectious Disease Management Market Outlook, By Pneumonia (2024-2032) ($MN)
  • Table 19 Global Infectious Disease Management Market Outlook, By Viral Infections (2024-2032) ($MN)
  • Table 20 Global Infectious Disease Management Market Outlook, By HIV/AIDS (2024-2032) ($MN)
  • Table 21 Global Infectious Disease Management Market Outlook, By Influenza (2024-2032) ($MN)
  • Table 22 Global Infectious Disease Management Market Outlook, By Hepatitis (2024-2032) ($MN)
  • Table 23 Global Infectious Disease Management Market Outlook, By COVID-19 (2024-2032) ($MN)
  • Table 24 Global Infectious Disease Management Market Outlook, By Fungal Infections (2024-2032) ($MN)
  • Table 25 Global Infectious Disease Management Market Outlook, By Parasitic Infections (2024-2032) ($MN)
  • Table 26 Global Infectious Disease Management Market Outlook, By End User (2024-2032) ($MN)
  • Table 27 Global Infectious Disease Management Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 28 Global Infectious Disease Management Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 29 Global Infectious Disease Management Market Outlook, By Ambulatory Care Centers (2024-2032) ($MN)
  • Table 30 Global Infectious Disease Management Market Outlook, By Research & Academic Institutes (2024-2032) ($MN)
  • Table 31 Global Infectious Disease Management Market Outlook, By Home Healthcare (2024-2032) ($MN)
  • Table 32 Global Infectious Disease Management Market Outlook, By Digital Health Solutions (2024-2032) ($MN)
  • Table 33 Global Infectious Disease Management Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.